[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554044":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group (A)","EXPERIMENTAL","Patients will be given uterotonics",[13],"Drug: oxytocin",{"label":15,"type":16,"description":17,"interventionNames":18},"Group (B)","PLACEBO_COMPARATOR","Patients will not be given uterotonics",[19],"Other: placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","oxytocin","Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"placebo","IV bolus of normal saline immediately with the uterine incision",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Abdalla Mousa","CONTACT","+201277664430","Dr_abdallamousa@yahoo.com",[38],{"facility":5,"status":39,"city":40,"state":26,"zip":26,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Cairo","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},[50],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":52,"investigatorFullName":33,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Lecturer of obgyn Cairo university","100554044","role-of-uterotonics-in-reducing-intraoperative-blood-loss-in-patients-with-pasd-undergoing-cesarean-hysterectomy-100554044",false,"NCT06493968","Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy","Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy","Inclusion Criteria:\n\n* Pregnancy of singleton living fetus\n* Previous one or more cesarean sections\n* Gestational age: \\> 32 weeks\n* The following ultrasound markers such as \"loss of clear retroplacental translucency\", \"myometrial thinning\", \"abnormal lacunae\", \"irregular bladder wall\", \"utero-vesicalhypervascularity\".\n* Preoperative hemoglobin more than 10 gm\u002Fdl\n* Cases with PAS that will undergoing CS Hysterectomy\n\nExclusion Criteria:\n\n* Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….\n* Any known or reported hypersensitivity to the used medication.\n* All cases with spontaneous placental separation at laparotomy.\n* All patients undergoing conservative management of PAS.\n* All cases which necessitate emergency termination.",true,"FEMALE","20 Years","40 Years",{"count":66,"type":67},70,"ESTIMATED","INTERVENTIONAL",[70],"NA","Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.",[73],"Placenta Accreta Spectrum","2024-07-02",{"date":76,"type":77},"2024-07-10","ACTUAL",{"date":79,"type":77},"2024-07-01",{"date":81,"type":67},"2024-12-31",{"name":5,"class":6},1]